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ACR70 responses, health outcome measures, CRP levels, and
overall incidence of adverse events among all groups. Forty-
four subjects (15.1%) discontinued the study, and the rate of
discontinuation was similar among treatment groups. Though
well-tolerated and safe, ERB-041 failed to demonstrate anti-
inflammatory efficacy in RA patients, despite evidence of
strong activity in preclinical arthritis models. Taken together,
these 2 studies suggest that selective ER agonism (both ER
and ER) would not have effects on regulation of inflamma-
tory response in RA.
There are several possible explanations. ERs are nu-
clear hormone receptors that can either directly bind to
estrogen response elements in gene promoters or serve as
cofactors with other transcription factors (i.e., NF-B/activator
protein 1) (5). Cytoplasmic ER and membrane-associated ER
affect specific kinase-signaling pathways. ERs have prominent
effects on immune function in both the innate and adaptive
immune responses. However, the roles of estrogen receptors
may be different between species, significantly limiting the easy
translation of preclinical studies (in animal models) into the
clinical setting (6).
Second, the role of estrogens in RA is the subject of
debate since both proinflammatory and antiinflammatory ef-
fects have been reported; important evidence of their dual role
is provided by their peripheral conversion to various proin-
flammatory or antiinflammatory metabolites at the level of the
RA synovial tissue. Recently, using estrone and 17-estradiol
as substrates, the production of 16-, 4-, and 2-hydroxylated
estrogens and their 4- and 2-methylation products in RA and
osteoarthritis (OA) synovial cells was evaluated (7). The levels
of 16-hydroxylated estrone/17-estradiol (16OH-estrone/
16OH-17-estradiol) were higher than the levels of all other
estrogen metabolites. RA synovial cells produced more
16OH-estrone than did OA synovial cells. Importantly, the
16OH-estrones did not inhibit tumor necrosis factor (TNF)
secretion, whereas all other estrogen metabolites had marked
inhibitory effects. These and similar findings indicate that
precursor estrogens are converted into proinflammatory me-
tabolites, particularly in RA synovial cells. RA synovial cells
mainly produce the proproliferative 16OH-estrone, which, in
addition to 16OH-17-estradiol, is one of the only two
estrogens studied that does not inhibit TNF secretion (8). A
preponderance of 16-hydroxyestrone is an unfavorable sign in
RA synovial inflammation.
Therefore, it must be considered that, even in the
presence of a normal interaction between endogenous estro-
gens (or agonists) and their functional ERs, an altered balance
in peripheral estrogen metabolites might induce different cell
(and clinical) responses in RA patients and promote unex-
pected effects.
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The heart in rheumatoid arthritis: contrasting or
misleading data from clinical research? Comment on
the article by Giles et al
To the Editor:
We read with great interest the article by Giles et al
(1), who recently reported that the progression to heart failure
in patients with rheumatoid arthritis (RA) may occur through
reduced myocardial mass rather than through hypertrophy.
Cardiac magnetic resonance imaging (MRI) was utilized as the
method for measuring left ventricular structure and function.
However, we believe that some methodologic problems under-
mine the strength of this research and its results.
First, the RA cohort in the Evaluation of Subclinical
Cardiovascular Disease and Predictors of Events in Rheuma-
toid Arthritis (ESCAPE RA) study was enrolled from October
2004 through May 2006, and the patients were recruited from
the Johns Hopkins Arthritis Center, where they were receiving
treatment. Giles and colleagues state that only their 75 study
subjects from the selected subset of the ESCAPE RA patients
(predefined as 40% of the RA patient sample) were scanned
with cardiac MRI. In contrast, the non-RA control subjects
were recruited between 2000 and 2002, from 1,086 subjects of
the Baltimore Multi-Ethnic Study of Atherosclerosis, a specific
subset (out of a total 6,814 subjects from 6 US communities)
that had been enrolled at the Johns Hopkins Field Center.
Only 788 of these control patients underwent examination by
cardiac MRI, and of those 788, only 225 were included in Giles
and colleagues’ report (1). The matching of RA patients with
3 control subjects each for comparison was randomized
(though Giles and colleagues did not describe their random-
ization method in detail). The fact that the 2 groups were
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enrolled at 2 different times and from 2 different studies may
have resulted in selection bias, thereby invalidating the results
of the study (2).
Moreover, some confounding factors (e.g., duration of
both hypertension and diabetes in the 2 groups) were not
considered. Cardiac MRI was recommended by Giles et al as
an imaging method that avoids overestimation of the left
ventricular mass in the setting of eccentric left ventricular
hypertrophy, a concern that is often relevant in RA. However,
there are few reports on the comparison of cardiac MRI with
transthoracic echocardiography, and a recent study has shown
that they have similar reliability in monitoring left ventricular
mass (3). Thus, echocardiography can be considered a well-
recognized technique for the morphologic and functional
evaluation of the left ventricle for both clinical and research
purposes, including evaluations of RA patients.
Rudominer et al recently published a report elaborat-
ing on this and describing the association of RA with increased
left ventricular mass (4). Their findings are consistent with
those of our previous studies of RA patients (5,6). Patients
with RA have both structural and functional left ventricular
involvement. In RA patients, we have previously demonstrated
that diastolic dysfunction (detected as relaxation abnormalities
during left ventricular filling) is directly correlated with struc-
tural changes in the left ventricle, specifically, changes involv-
ing left ventricular mass, interventricular septal thickness, and
left ventricular posterior wall thickness (6). All of these seem
to be features of the systemic disease process in RA, and
diastolic dysfunction seems to be a consequence of left ven-
tricular structural changes. An autopsy-based study revealed
structural cardiac involvement (7). In a meta-analysis of pre-
viously published reports (8) we ascertained the effect size of
RA on left ventricular mass index in patients compared with
healthy controls; comparison was rigorous in the studies con-
sidered in the meta-analysis. Moreover, other studies contrib-
ute to the growing body of research on this topic, confirming
structural left ventricular involvement in RA (9,10). In conclu-
sion, we believe that the data collected by Giles and colleagues
mislead the scientific community, while a large amount of
research confirms that left ventricular structural and functional
changes are one of the established clinical features of RA.
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Reply
To the Editor:
We thank Dr. Corrao and colleagues for their letter.
They question whether issues of bias may have impugned our
finding that left ventricular mass, assessed using cardiac MRI,
was on average 18% lower among RA patients, compared with
a demographically matched control group, both without known
cardiovascular disease (CVD). Furthermore, they assert the
validity of echocardiography for the comparison of left ven-
tricular mass between RA and non-RA groups.
To clarify, ESCAPE RA is an ancillary study of the
Baltimore Multi-Ethnic Study of Atherosclerosis (MESA) and
not a different study. ESCAPE RA participants undergo the
same testing, using the same protocols, facilities, equipment,
and quality control measures as MESA. In addition, data are
managed by the same coordinating center, images are inter-
preted by the same reading centers, and laboratory specimens
are processed at the same facilities. We scanned consecutive
ESCAPE RA enrollees without contraindications to cardiac
MRI until the predetermined subsample allotment was met.
As we reported, there were no differences in clinical character-
istics between RA patients who did and those who did not
undergo cardiac MRI scanning.
Regarding potential incompatibility between the RA
and control groups as a threat to the validity of our findings, we
acknowledge that selection bias is a possibility in any study of
this type. However, it is unlikely to be of sufficient magnitude
to invalidate our findings, for several reasons. First, the main
variables under study (cardiac MRI parameters) are subclini-
cal, which decreases the likelihood that cases with abnormal
values were included or selected. Additionally, through fre-
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